A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Novo Nordisk A/S
Study ID
NCT07605052
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • Cagrilintide B — DRUG
    Cagrilintide B will be administered subcutaneously.
  • Cagrilintide D — DRUG
    Cagrilintide D will be administered subcutaneously.

Study Details

The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.

Key Dates

First listed
May 22, 2026
Start date
May 20, 2026
Status verified
Jul 2026
Primary completion
Sep 3, 2026
Completion
Sep 3, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cagrilintide B
    Participants will receive cagrilintide B subcutaneously once weekly for 5 weeks.
  • Experimental: Cagrilintide D
    Participants will receive cagrilintide D subcutaneously once weekly for 5 weeks.

Primary Outcome Measure

AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide [ Time Frame: From Pre-dose at Day 29 to Day 36 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion, PhoenixTempeArizona85283-

Find similar trials in Tempe, AZ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Celerion, Phoenix· Tempe, AZ

Related Studies